These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 741422)

  • 1. [The effects of prolonged treatment with gliclazide on the course of proteinuria and renal function in diabetic nephropathy].
    Lagrue G; Kazandjian M; Gumpelson A; Riveline B
    Therapie; 1978; 33(5):629-37. PubMed ID: 741422
    [No Abstract]   [Full Text] [Related]  

  • 2. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A; Hayashi K; Saruta T
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin converting enzyme inhibitor and chronic renal failure.
    Sitprija V; Lumlertgul D
    J Med Assoc Thai; 1993 Jul; 76(7):359-67. PubMed ID: 8089635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of diabetic nephropathy.
    Wittmann I; Molnár GA; Degrell P; Wagner Z; Tamaskó M; Laczy B; Brasnyó P; Wagner L; Nagy J
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S36-42. PubMed ID: 15955373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of indomethacin on the proteinuria of diabetic nephropathy.
    Jacob CK; Date A; Kirubakaran MG; Shastry JC; Johny KV
    J Assoc Physicians India; 1984 Aug; 32(8):723-5. PubMed ID: 6511749
    [No Abstract]   [Full Text] [Related]  

  • 7. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of the angiotensin-converting enzyme inhibitor enalapril on the rates of progression of chronic kidney failure in patients with different degrees of functional kidney disorders].
    Esaian AM; Kaiukov IG; Titova VA
    Ter Arkh; 1995; 67(6):57-9. PubMed ID: 7667785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience with diamicron treatment of diabetics].
    Velikov VK; Shubina IO; Saltykov BB; Frolova AI
    Klin Med (Mosk); 1984 Nov; 62(11):99-101. PubMed ID: 6441072
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
    Lo MK; Lee KF; Chan NN; Leung WY; Ko GT; Chan WB; So WY; Ng MC; Ho CS; Tam JS; Lam CW; Tong PC; Chan JC
    Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allograft diabetic nephropathy may progress to end-stage renal disease.
    Salifu MO; Nicastri AD; Markell MS; Ghali H; Sommer BG; Friedman EA
    Pediatr Transplant; 2004 Aug; 8(4):351-6. PubMed ID: 15265161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
    Sanaka T; Akizawa T; Koide K; Koshikawa S
    Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lack of effect of ACE inhibition on severe proteinuria in diabetic nephropathy--a 6-month-long study].
    Hay U; Ludvik B; Gisinger C; Schernthaner G
    Schweiz Med Wochenschr; 1988 Feb; 118(5):165-9. PubMed ID: 3278375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lercanidipine in diabetic patients with renal failure].
    Robles NR; Pastor L; Manjón M; Ocón J; Gómez Campderá F; Herrera J; Villatoro J; Calls J; Torrijos J; Rodríguez Villareal I; Rodríguez Martínez MA; Méndez ML; Morey A; Martínez Fernández J; Marco J; Liébana A; Rincón B; Tornero F
    Nefrologia; 2004; 24(4):338-43. PubMed ID: 15455493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-platelet therapy in diabetic and non-diabetic progressive renal failure.
    Gordge MP; Rylance PB; Neild GH
    Clin Nephrol; 1992 Jan; 37(1):53-5. PubMed ID: 1541067
    [No Abstract]   [Full Text] [Related]  

  • 17. [Difficult therapy in patients with renal failure. What protects, what damages the kidneys?].
    Stiefelhagen P
    MMW Fortschr Med; 2005 Apr; 147(16):4-6. PubMed ID: 16392389
    [No Abstract]   [Full Text] [Related]  

  • 18. Identifying and slowing progressive chronic renal failure.
    Curtis B; Barrett BJ; Levin A
    Can Fam Physician; 2001 Dec; 47():2512-8. PubMed ID: 11785282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal health in Chile.
    Escobar C; Arce I; Jara A; Mezzano S; Ardiles L
    Ren Fail; 2006; 28(8):639-41. PubMed ID: 17162421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
    Sinsakul M; Sika M; Rodby R; Middleton J; Shyr Y; Chen H; Han E; Lehrich R; Clyne S; Schulman G; Harris R; Lewis J
    Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.